News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Enabling a new era in minimally invasive obesity treatment across Europe
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Subscribe To Our Newsletter & Stay Updated
